December 11, 2020 -- AstraZeneca said it will use one of the components of the Sputnik V vaccine, Russia's COVID-19 vaccine, in its own clinical trials for a COVID-19 vaccine. The component was offered by the Russian Direct Investment Fund (RDIF; Russia's sovereign wealth fund) and the Gamaleya Center.
Due to start the studies later this month, AstraZeneca will use the adenoviral vector type Ad26 in clinical trials after the Sputnik V vaccine showed a more than 90% efficacy against COVID-19. Sputnik V uses two adenoviral vectors for a prime and a boost immunization that helps avoid immunity to the first vector. This forms after the first inoculation and thus raises efficacy and creates long-term immunity, RDIF said.
Adding in Ad26 should help AstraZeneca's vaccine efficacy and the partners plan to start joint production after the new vaccine demonstrates its efficacy in the course of AstraZeneca's clinical trials. RDIF also said it hopes other vaccine producers will follow their example and share vaccine information.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
